Replimune price to book ratio REPL
Market value divided by the book value of the company's net assets, since 2018.
- Today, Nov 2, 2026
- 9.0×
- 8-year median
- 2.5×
- Against its 8-year history
- 97th
- percentile: 0 is its lowest day, 100 its highest
- 8-year range
- 0.6× to 13.8×
- Peer median
- 5.5×
Replimune's price to book ratio is 9.0× as of Nov 2, 2026.
That is above its 8-year median of 2.5×, higher than on 97% of days in the last 8 years.
Over that time it ranged from 0.6× in Jul 2025 to 13.8× in Aug 2026.
The median for 10 biotech stocks of a similar size is 5.5×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 9.0× | 0.9× | 13.8× |
| 2025 | 3.0× | 0.6× | 3.2× |
| 2024 | 2.2× | 0.9× | 2.7× |
| 2023 | 1.1× | 0.9× | 3.7× |
| 2022 | 3.5× | 1.6× | 3.5× |
| 2021 | 2.8× | 2.7× | 7.8× |
| 2020 | 6.7× | 1.7× | 9.1× |
| 2019 | 4.1× | 2.2× | 4.1× |
| 2018 | 2.1× | 2.1× | 3.2× |
Against its peers
Companies in Biotechnology nearest Replimune's size, closest first, today.
| Company | Price to book ratio |
|---|---|
| REPLReplimune | 9.0× |
| VCELVericel | 5.6× |
| ADMAAdma Biologics | 6.1× |
| MGTXMeiraGTx | 4.2× |
| KRYSKrystal Biotech | 6.4× |
| RGENRepligen | 4.6× |
| TECHBIO-TECHNE | 5.4× |
| HALOHalozyme Therapeutics | 102× |
| NBIXNeurocrine Biosciences | 4.0× |
| PLXProtalix BioTherapeutics | 2.9× |
| EXELExelixis | 9.4× |
| Peer median | 5.5× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Replimune
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.